

A list of all abbreviations and terms appearing in this issue of *Therapy*

|                  |   |         |  |         |  |
|------------------|---|---------|--|---------|--|
| AACE             | American Association of Clinical Endocrinologists | CV      | Cardiovascular   | GLUT    | Glucose transporter  |
| ACC              | Acetyl CoA carboxylase                            | CVD     | Cardiovascular disease   | GP      | General practitioner   |
| ACE              | Angiotensin-converting enzyme                     | CYP     | Cytochrome P   | GRE     | Gradient echo  |
| ACTH             | Ectopic adrenocorticotrophic hormone              | DB      | Double-blinded   | HbA1c   | Hemoglobin A1c   |
| ADA              | American Diabetes Association                     | DBP     | Diastolic blood pressure   | HDL     | High-density lipoprotein                                       |
| ADL              | Activities of daily living                        | DC      | Diabetes control group   | HMG-CoA | 3-hydroxy-3-methylglutaryl coenzyme A                          |
| ADOPT            | A Diabetes Outcome Progression Trial              | DCCT    | Diabetes Control and Complication Trial  | HOMA    | Homeostasis model assessment of percent $\beta$ -cell function |
| AE               | Adverse event                                     | DEXA    | Dual energy X-ray absorptiometry   | HR      | Hazard ratio   |
| AGT              | Angiotensinogen                                   | DLCO    | Single-breath carbon monoxide diffusing capacity                               | IAF     | Intra-abdominal fat  |
| AHO              | Albright hereditary osteodystrophy                | DLQI    | Dermatology Life Quality Index   | IDF     | International Diabetes Federation                              |
| ALAT             | Alanine aminotransferase                          | DM      | Diabetes mellitus  | Ig      | Immunoglobulin   |
| ALT              | Alanine transferase                               | DM2     | Type 2 Diabetes Mellitus   | IRAS    | Insulin Resistance Atherosclerosis Study                       |
| AMPK             | AMP-activated protein kinase                      | DPP IV  | Dipeptidylpeptidase IV   | LbL     | <i>Lycium barbarum L.</i>                                      |
| Ang II           | Angiotensin II                                    | DPP     | Diabetes Prevention Program  | LCD     | Low-calorie diet   |
| ANOVA            | Analysis of variance                              | DREAM   | Diabetes Reduction Assessment with Ramapril and Rosiglitazone Medication trial | LDFC    | Low-dose fixed combination                                     |
| Apo B            | Apo lipoprotein B                                 | DRG     | Diagnosis-related group  | LDL     | Low-density lipoprotein  |
| ARIC             | Atherosclerosis Risk in Communities               | DXA     | X-ray absorptiometry   | LYG     | Life-year gained   |
| ASAT             | Aspartate aminotransferase                        | EGIR    | European Group for Study of Insulin Resistance                                 | MBD     | Metabolic bone disease   |
| ASMM             | Appendicular skeletal muscle mass                 | EMEA    | European Agency for the Evaluation of Medicinal Products                       | MC      | Multicenter  |
| AT               | Adipose tissue                                    | ESH/ESC | European Society of Hypertension and European Society of Cardiology            | MCP     | Monocyte chemoattractant protein                               |
| AT1              | Angiotensin Type 1                                |         |  | MET     | Metformin  |
| ATP              | Adult Treatment Panel                             |         |  | MI      | Myocardial infarction  |
| b.i.d            | Twice daily                                       |         |  | MITT    | Modified intent-to-treat                                       |
| BM               | Bowel movement                                    | ESRD    | End-stage renal disease  | MR      | Meal replacement   |
| BMC              | Bone mineral content                              | FA      | Fatty acid   | NASH    | Nonalcoholic steatohepatitis                                   |
| BMD              | Bone mineral density                              | fAd     | Adiponectin complete molecule  | NC      | Normal control   |
| BMR              | Basal metabolic rate                              | FAS     | Fatty acid synthase  | NCEP    | National Cholesterol Education Panel                           |
| BP               | Blood pressure                                    | FAA     | Free fatty acid  | NCEP    | National Cholesterol Education Program                         |
| BPD              | Biliopancreatic diversion                         | FFM     | Fat-free mass  | NGT     | Nasogastric intubation   |
| BSA              | Body surface area                                 | FFS     | Focal segmental glomerulosclerosis   | NHANES  | National Health and Nutrition Examination Survey               |
| CARDIA           | Coronary Artery Risk Development in Young Adults  | FGB     | Food and Nutrition Board   | NO      | Nitric oxide   |
| CCK              | Cholecystokinin                                   | FPG     | Fasting plasma glucose   | NPY     | Neuropeptide Y   |
| CCM              | Cerebral cavernous malformations                  | FRC     | Functional residual capacity   | NS      | Not significant  |
| CGRP             | Calcitonin gene-related peptide                   | FVC     | Forced vital capacity  | NYHA    | New York Heart Association Functional Classification           |
| CHD              | Coronary heart disease                            | gAd     | Adiponectin globular fraction  | OA      | Osteoarthritis   |
| CHF              | Congestive heart failure                          | GB      | Glibenamide  | OSA     | Obstructive sleep apnea  |
| CI               | Confidence interval                               | GERD    | Gastro-esophageal reflux disease   | PAI     | Plasminogen activation inhibitor                               |
| CIMT             | Carotid intima-media thickness                    | GFR     | Glomerular filtration rate   | PASI    | Psoriasis Area and Severity Index                              |
| CK               | Creatine kinase                                   | GH      | Growth hormone   | PC      | Placebo-controlled   |
| CKD              | Chronic kidney disease                            | GHRH    | Growth hormone-releasing hormone   | PCNA    | Proliferating cell nuclear antigen                             |
| C <sub>max</sub> | Peak concentration                                | GI      | Gastrointestinal   | PCOS    | Polycystic ovaries syndrome                                    |
| CMS              | Cardiometabolic syndrome                          | GIP     | Glucose-dependent insulinotropic polypeptide                                   | PFT     | Pulmonary function test  |
| CRP              | C-reactive protein                                | GLP     | Glucagon-like peptide  | PHP1a   | Pseudohypoparathyroidism type 1a                               |
| CTX              | Cyclophosphamide                                  |         |  | Pio     | Pioglitazone   |

## GLOSSARY

|         |   |      |   |                  |  |
|---------|---|------|---|------------------|--|
| PKBPE   | <i>Pinus koraiensis</i> bark procyanidins extract   | REIN | Ramipril Efficacy In Nephropathy          | TG               | Triglyceride                           |
| PI      | Placebo   | Rep  | Repaglinide                               | TLC              | Thin-layer chromatography              |
| PO      | Orally  | RIO  | Rimonabant in obesity                     | TLC              | Total lung capacity                    |
| POI     | Postoperative ileus   | RIS  | Reactive oxygen species                   | t <sub>max</sub> | Time to peak concentration             |
| PP      | Pancreatic polypeptide  | Ros  | Rosiglitazone                             | TNF              | Tumor necrosis factor                  |
| PPAR    | Peroxisome proliferator-activated receptor  | RPF  | Renal plasma flow                         | TRIPOD           | Troglitazone in Prevention of Diabetes |
| PRETEND | Percepción de las Recomendaciones Establecidas para el Tratamiento antihipertensivo En relación con la Necesidad de utilización de bajas Dosis en combinación | RR   | Relative risk                             | PIPOD            | Pioglitazone in Prevention of Diabetes |
|         |   | RSG  | Rosiglitazone                             | TSH              | Thyroid-stimulating hormone            |
|         |   | RV   | Residual volume                           | TUMS             | Tehran University of Medical Sciences  |
|         |   | RXR  | Retinoid-X receptor                       | TZD              | Thiazolidinedione                      |
|         |   | RYGB | Roux-en-Y gastric bypass                  | UAE              | Urinary albumin excretion              |
|         |   | s.c. | Subcutaneous                              | UKPDS            | UK Prospective Diabetes Study          |
|         |   | SBP  | Systolic blood pressure                   | UL               | Upper limit                            |
|         |   | SD   | Standard deviation                        | u-NTX            | Urinary N-telepeptides                 |
|         |   | SE   | Standard error                            | USRDS            | US Renal Data System                   |
| PREVEND | Prevention of Renal and Vascular End stage Disease  | SE   | Spin echo                                 | UVB              | Ultraviolet-B                          |
|         |   | SHBG | Sex hormone binding globulin              | VAS              | Visual analog scale                    |
| PTH     | Parathyroid hormone   | SI   | Insulin sensitivity                       | VAT              | Visceral adipose tissue                |
| PWS     | Prader-Willi syndrome   | SLE  | Systemic lupus erythematosus              | VC               | Vital capacity                         |
| PYY     | Peptide YY  | SM   | Skeletal muscle                           | VIP              | Vasointestinal polypeptide             |
| R       | Randomized  | SRBP | Sterol regulatory element binding protein | VLCD             | Very-low-calorie diet                  |
| RAAS    | Renin-angiotensin-aldosterone system  | SUR  | Sulfonylurea receptor                     | VLDL             | Very-low-density lipoprotein           |
| RAS     | Renin-angiotensin system  | T2DM | Type 2 diabetes mellitus                  | WC               | Waist circumference                    |
| RCD     | Reduced-calorie diet  | TC   | Total cholesterol                         | WHR              | Waist:hip ratio                        |
| RCT     | Randomized, controlled trial  | TEAE | Treatment-emergent adverse events         | Wt               | Weight                                 |
| RDI     | Respiratory disturbance index   |      |   |                  |  |